ArticleEchocardiography (Mount Kisco, N.Y.)2026
Mavacamten's Dose-Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling.
Article in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHypertrophic obstructive cardiomyopathy (HOCM) causes dynamic left ventricular outflow tract (LVOT) obstruction and disabling symptoms; many patients do not respond to conventional agents. Mavacamten, a selective cardiac myosin inhibitor, improves gradients, but the dose-time response in routine practice remains unclear.
aimsTo evaluate longitudinal echocardiographic, biomarker, and safety changes associated with clinically guided mavacamten therapy compared with conventional pharmacotherapy in symptomatic HOCM.
methodsIn this single-center prospective comparative cohort study, 95 symptomatic HOCM patients were included, of whom 48 received mavacamten and 47 received conventional pharmacotherapy. Mavacamten was initiated at 2.5 mg daily and titrated (2.5-10 mg) based on resting LVOT gradient (LVOTG) and ejection fraction (LVEF). Follow-up assessments were performed at baseline and at scheduled visits at 3, 6, and 9 months. Longitudinal echocardiographic trajectories were analyzed using observed mean changes with 95% confidence intervals (CIs), and baseline imbalance was assessed using inverse probability weighting. The predefined LVOTG response endpoint was defined as a reduction in resting LVOTG of ≥ 30 mmHg from baseline at the last available follow-up.
resultsMavacamten was associated with a downward trajectory in resting LVOTG during follow-up, whereas the control group remained relatively stable. BNP decreased significantly in the mavacamten group, whereas no significant paired change was observed in the control group. The predefined LVOTG response endpoint was achieved by 9 of 48 patients (18.8%) in the mavacamten group and 1 of 42 patients (2.4%) in the control group (Fisher exact p = 0.0175; OR = 9.46, 95% CI 1.14-78.20). No patient experienced LVEF < 50%.
conclusionsIn symptomatic HOCM, clinically guided mavacamten therapy was associated with reductions in resting LVOT gradient and BNP, while LVEF remained preserved during short-term follow-up. These findings support individualized dose titration with echocardiographic monitoring, while dose-stratified and response analyses should be interpreted cautiously because of limited subgroup sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.